1430812-34-2

Upstream product

• 1430812-31-9 C₂₀H₂₁BrO₅ 
• 1430812-48-8 N'-(9-bromo-8-methoxy-3,4-dihydrobenzo[b]oxepin-5(2H)-ylidene)-4-methylbenzenesulfonohydrazide 
• 1430812-47-7 9-bromo-8-methoxy-3,4-dihydrobenzo[b]oxepin-5(2H)-one 
• 1430812-46-6 9-bromo-8-methoxy-2,3,4,5-tetrahydrobenzo[b]oxepin-5-ol 
• 1430812-45-5 9-bromo-8-methoxy-2,5-dihydrobenzo[b]oxepin-5-ol 
• 1430812-44-4 1-(2-(allyloxy)-3-bromo-4-methoxyphenyl)prop-2-en-1-ol 
• 1430812-43-3 2-(allyloxy)-3-bromo-4-methoxybenzaldehyde 
• 63638-85-7 3-bromo-2-hydroxy-4-methoxybenzaldehyde 
• 621-59-0 isovanillin 

Relevant academic research and scientific papers

Design, synthesis and anticancer properties of 5-arylbenzoxepins as conformationally restricted isocombretastatin A-4 analogs

A series of novel benzoxepins 6 was designed and prepared as rigid-isoCA-4 analogs according to a convergent strategy using the coupling of N-tosylhydrazones with aryl iodides under palladium catalysis. The most potent compound 6b, having the greatest resemblance to CA-4 and isoCA-4 displayed antiproliferative activity at nanomolar concentrations against various cancer cell lines and inhibited tubulin assembly at a micromolar range. In addition, benzoxepin 6b led to the arrest of HCT116, K562, H1299 and MDA-MB231 cancer cell lines in the G2/M phase of the cell cycle, and strongly induced apoptosis at low concentrations. Docking studies demonstrated that benzoxepin 6b adopt an orientation similar to that of isoCA-4 at the colchicine binding site on β-tubulin.